Abstract:Objective To explore the clinical values of propofol and remimazolam besylate in painless fiberoptic bronchoscopy.Methods Sixty patients who were scheduled to receive painless fiberoptic bronchoscopy in Shifang People's Hospital from January 2020 to December 2022 were selected, and were divided into the propofol group (P group) and the remimazolam besylate group (R group) by the random number table method, with 30 patients in each group. The change trends of hemodynamic parameters, indicators of anesthetic effects and recovery quality, levels of blood glucose and lactate, and anesthesia-related adverse events were compared between the two groups.Results The postoperative recovery time of the R group was shorter than that of the P group (P < 0.05). There was no significant difference between the R group and the P group in the anesthetic onset time and the time to leave the recovery room (P > 0.05). The HR, SpO2, and MAP at T0, T1, T2 and T3 in the two groups were compared, and the results revealed that all these indicators were different among the time points (P < 0.05) and that the MAP (P < 0.05) rather than HR and SpO2 (P >0.05) was different between the two groups. The change trend of MAP (P < 0.05) but not that of HR and that of SpO2 (P >0.05) was different between the two groups. There was no significant difference in the anesthetic effects between the two groups (P > 0.05). Comparison of the Ramsay scores at different time points in the two groups demonstrated that they were different among the time points (P < 0.05) but not between the groups (P > 0.05), and that the change trends of the Ramsay scores were not different between the two groups (P > 0.05). The levels of blood glucose and lactate before surgery, immediately after surgery and 4 hours after surgery in the two groups were compared, which showed that they were different among the time points (P <0.05) but not between the two groups (P > 0.05), and that the change trends of the levels of blood glucose and lactate were not different between the two groups (P > 0.05). The incidence of adverse events in the R group was lower than that in the P group (P < 0.05).Conclusion Compared with propofol, remimazolam besylate is more conducive to hemodynamic stability in patients undergoing painless fiberoptic bronchoscopy, and shortens the recovery time while reducing the incidence of anesthesia-related adverse events.